Humacyte, Inc. (HUMA) has a MoatMap StockRank of 1/100 based on Quality (15/100), Value (28/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. Humacyte, Inc. is another small-cap US healthcare (biotech) company ($191M MCap) with an extremely low SmartRank (SR: 0.2), poor quality (Q:13), and a 'STRONG_SELL' signal. As with Genelux, this type of early-stage, speculative biotech company does not align with the fund's philosophy of investing in 'quality compounders' with durable moats and predictable reinvestment runways. There is no identified macro tailwind to offset the inherent risks.
Humacyte, Inc. is a clinical-stage biotechnology company developing bioengineered human acellular vessels (HAVs) for vascular repair, reconstruction, and replacement. Its proprietary technology aims to create off-the-shelf, universally implantable vessels that avoid rejection, addressing significant unmet needs in vascular surgery. The company holds a unique position in regenerative medicine with the potential to offer a superior alternative to synthetic grafts and autologous vessels.
| Price | $1.05 |
| Market Cap | $233M |
| P/E (Forward) | -5.16 |
| Price/Book | 51.58 |
| Return on Equity | -409.5% |
| Return on Invested Capital | -30.2% |
| Debt/Equity | 572.10 |
| Gross Margin | 0.0% |
| Operating Margin | -5704.0% |
| Revenue Growth | -4.3% |
| Free Cash Flow | $-65M |
Humacyte, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).